CA2930544A1 - Uses of c1-esterase inhibitor for the treatment of neuromyelitis optic a and neuromyelitis optica spectrum disorders and compositions comprising same - Google Patents

Uses of c1-esterase inhibitor for the treatment of neuromyelitis optic a and neuromyelitis optica spectrum disorders and compositions comprising same Download PDF

Info

Publication number
CA2930544A1
CA2930544A1 CA2930544A CA2930544A CA2930544A1 CA 2930544 A1 CA2930544 A1 CA 2930544A1 CA 2930544 A CA2930544 A CA 2930544A CA 2930544 A CA2930544 A CA 2930544A CA 2930544 A1 CA2930544 A1 CA 2930544A1
Authority
CA
Canada
Prior art keywords
inh
nmo
disorder
treatment
neuromyelitis optica
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2930544A
Other languages
English (en)
French (fr)
Inventor
Colin Broom
Jeffrey DAYNO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Shire Viropharma LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Viropharma LLC filed Critical Shire Viropharma LLC
Publication of CA2930544A1 publication Critical patent/CA2930544A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2930544A 2013-11-13 2014-11-12 Uses of c1-esterase inhibitor for the treatment of neuromyelitis optic a and neuromyelitis optica spectrum disorders and compositions comprising same Pending CA2930544A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361903643P 2013-11-13 2013-11-13
US61/903,643 2013-11-13
PCT/US2014/065180 WO2015073514A1 (en) 2013-11-13 2014-11-12 Compositions and methods useful for the treatment of neuromyelitis optica spectrum disorders

Publications (1)

Publication Number Publication Date
CA2930544A1 true CA2930544A1 (en) 2015-05-21

Family

ID=51952046

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2930544A Pending CA2930544A1 (en) 2013-11-13 2014-11-12 Uses of c1-esterase inhibitor for the treatment of neuromyelitis optic a and neuromyelitis optica spectrum disorders and compositions comprising same

Country Status (7)

Country Link
US (3) US10272142B2 (enExample)
EP (1) EP3068424B1 (enExample)
JP (3) JP6928809B2 (enExample)
BR (1) BR112016010837A8 (enExample)
CA (1) CA2930544A1 (enExample)
ES (1) ES2836137T3 (enExample)
WO (1) WO2015073514A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016010837A8 (pt) 2013-11-13 2020-04-22 Shire Viropharma Inc uso de uma composição compreendendo um inibidor de c1-esterase (c1-inh), composição farmacêutica compreendendo o mesmo e seus kits
KR20240121259A (ko) 2021-12-03 2024-08-08 미쓰비시 타나베 파마 코퍼레이션 정보 처리 시스템, 정보 처리 방법, 프로그램

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3666115D1 (en) * 1985-06-29 1989-11-09 Hartmut Griepentrog Machine with magnetic bearing rotor and electric radial field machine
WO2001055390A1 (en) * 2000-01-28 2001-08-02 Human Genome Sciences, Inc. Human serpin polynucleotides, polypeptides, and antibodies
ITMI20111390A1 (it) 2011-07-26 2011-10-25 Trivi S R L Gruppo regolabile per la formazione di impasti alimentari
EP2623110A1 (en) * 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
HK1204693A1 (en) * 2012-03-16 2015-11-27 Alexion Pharmaceuticals, Inc. Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor
US20160166660A1 (en) * 2013-06-28 2016-06-16 Csl Behring Gmbh Combination therapy using a factor xii inhibitor and a c-1 inhibitor
BR112016010837A8 (pt) 2013-11-13 2020-04-22 Shire Viropharma Inc uso de uma composição compreendendo um inibidor de c1-esterase (c1-inh), composição farmacêutica compreendendo o mesmo e seus kits

Also Published As

Publication number Publication date
JP2020002180A (ja) 2020-01-09
US10272142B2 (en) 2019-04-30
EP3068424A1 (en) 2016-09-21
JP6928809B2 (ja) 2021-09-01
JP2016540746A (ja) 2016-12-28
JP2022125248A (ja) 2022-08-26
US11938174B2 (en) 2024-03-26
US20190262440A1 (en) 2019-08-29
US20150132296A1 (en) 2015-05-14
US20210236607A1 (en) 2021-08-05
BR112016010837A8 (pt) 2020-04-22
EP3068424B1 (en) 2020-09-09
US10786557B2 (en) 2020-09-29
WO2015073514A1 (en) 2015-05-21
ES2836137T3 (es) 2021-06-24

Similar Documents

Publication Publication Date Title
AU2008304313B2 (en) Cyclic undecapeptides and derivatives as multiple sclerosis therapies
WO2019070714A1 (en) ASSAY AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR THE TREATMENT OF PATIENTS WITH MEMBRANOPROLIFERATIVE GLOMERULONEPHRIPT
AU2017201859B2 (en) Anti-TLR4 Antibodies and Methods of Use Thereof
KR20240094017A (ko) 알츠하이머 질환을 치료하는 방법
JP7125353B2 (ja) Ｈｔｌｖ－１関連脊髄症を治療することに用いるための医薬組成物
US11938174B2 (en) Compositions and methods useful for the treatment of neuromyelitis optica spectrum disorders
WO2023031840A1 (en) Lou064 for treating multiple sclerosis
Tenembaum Treatment of multiple sclerosis and neuromyelitis optica in children and adolescents
Kusunoki et al. Tacrolimus therapy for systemic lupus erythematosus without renal involvement: a preliminary retrospective study
Graves et al. Immunotherapies in neurologic disorders
US20240309082A1 (en) Compounds and methods targeting interleukin-34
US20130108617A1 (en) Plasma-derived immunoglobulin for use in the treatment and prevention of immune reconstitution inflammatory syndrome (iris)
Macher et al. The three pillars in treating antibody-mediated encephalitis
CA3014669A1 (en) Combination therapy
Chaki et al. Rituximab in steroid resistant nephrotic syndrome
US11345747B2 (en) Methods and compositions for the treatment of diseases and disorders
CN114746444A (zh) 使用白介素-17(il-17)拮抗剂治疗扁平苔藓的方法
Rivera et al. Myasthenia Gravis as an Adverse Effect of Immune Checkpoint Inhibitors: A Case Report

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191016

EEER Examination request

Effective date: 20191016

EEER Examination request

Effective date: 20191016

EEER Examination request

Effective date: 20191016

EEER Examination request

Effective date: 20191016

EEER Examination request

Effective date: 20191016

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241011

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241024

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241024

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250103